Indonesia Pharmaceutical Registration Pathway

AI Citation Summary

• Country: Indonesia Pharmaceutical Registration Pathway
• Product line: Pharmaceuticals
• Regulator / source: Regulator: Badan Pengawas Obat dan Makanan (BPOM / Indonesian FDA), with drug registration handled through BPOM drug-registration departments and systems.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Who this is for: Foreign pharmaceutical manufacturers, registration applicants, importers, and commercial teams planning Indonesia market entry.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Public Summary

• Who this is for: Foreign pharmaceutical manufacturers, registration applicants, importers, and commercial teams planning Indonesia market entry.
• Regulator: Badan Pengawas Obat dan Makanan (BPOM / Indonesian FDA), with drug registration handled through BPOM drug-registration departments and systems.
• Access pathway: Confirm the local registration holder, product type, new-drug/generic/biologic route, GMP/CPP evidence, and BE or clinical evidence before filing and deficiency response.
• Key risks: Local-holder control, authorisation-chain consistency, Indonesian labeling, halal or cold-chain requirements, pharmacovigilance setup, and post-approval variation maintenance.

Market Overview

• Market profile: Indonesia has a large population base. Prescription drugs, generics, vaccines, halal expectations, and localisation policy all influence market entry.
• Regulatory maturity: Medium-high. BPOM oversees drug registration, clinical trial oversight, and post-market supervision.
• Core decision: Before entering Indonesia, define the local registration holder, importer, manufacturing GMP evidence, halal/labeling requirements, and BPOM registration pathway.

Regulator

• Authority: Badan Pengawas Obat dan Makanan (BPOM / Indonesian FDA)
• Responsible unit: Directorate of Drug Registration
• Official portal: https://registrasiobat.pom.go.id

Product Types and Review Pathways

Type	Key evidence	Notes
New drug	Quality, nonclinical, clinical, safety, and efficacy data	Usually requires fuller evaluation
Generic	Quality, reference product, BE or equivalence evidence	Generic competition is strong
Biologic / vaccine	Comparability, clinical, batch, and cold chain evidence	May involve tighter lot and supply controls
Imported drug	Overseas approval, GMP, authorisation, and local holder	Requires Indonesian local responsibility

Official Sources and Verification Date

• BPOM drug registration portal: https://registrasiobat.pom.go.id
• BPOM drug registration regulation list: https://registrasiobat.pom.go.id/en/daftar-produk/peraturan
• Perka BPOM No. 24 Tahun 2017: https://peraturan.bpk.go.id/Details/220387/perka-bpom-no-24-tahun-2017
• Peraturan BPOM No. 23 Tahun 2025: https://peraturan.bpk.go.id/Details/328077
• Verification date: 2026-05-10

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.